electroCore,

electroCore, FCF Yield

The Free Cash Flow Yield of electroCore, (ECOR) as of Oct 18, 2026 is -15.75 %. In the previous year, Free Cash Flow Yield was -13.26 % — a change of 18.78% (lower).

FCF Yield

-15.75 %

YoY

18.78%

Last updated:

Free Cash Flow Yield of electroCore, is 2025 -15.75 % . Free Cash Flow Yield of electroCore, was 2024 -13.26 % . It decreases by 18.78% lower compared to the previous year.

The electroCore, FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-90.41 USD
Jan 1, 2019
-86.12 USD
Jan 1, 2020
-38.26 USD
Jan 1, 2021
-26.00 USD
Jan 1, 2022
-31.76 USD
Jan 1, 2023
-28.38 USD
Jan 1, 2024
-13.26 USD
Jan 1, 2025
-15.75 USD
The electroCore, FCF Yield history
YEARFCF YieldYoY
-15.75 %+18.78%
-13.26 %-53.29%
-28.38 %-10.64%
-31.76 %+22.15%
-26.00 %-32.04%
-38.26 %-55.58%
-86.12 %-4.75%
-90.41 %+85.97%
-48.62 %+90.47%
-25.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Free Cash Flow Yield of electroCore, is -15.75 % in 2025.

Free Cash Flow Yield of electroCore, changed from -13.26 % to -15.75 %, representing a 18.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield electroCore, since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's electroCore, with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — electroCore,

All Key Metrics — electroCore,